Shares of Edgewise Therapeutics EWTX soared 30% in the pre-market trading on Thursday after it reported positive top-line data of EDG-7500 from an early-stage study in healthy subjects and Part A ...

Below is a chart showing EWTX's trailing twelve month trading history, with the $25 strike highlighted in orange: For the various different available expirations for NBIX options, ACLS options, or ...

Edgewise Therapeutics, Inc. (EWTX) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a biopharmaceutical company, focuses on developing therapies for the treatment of muscle disorders.

Edgewise Therapeutics (EWTX) is scheduled to report earnings on February 20, 2025. The last reported earnings were for reported on November 7, 2024 for Q3. Q ...

EWTX is evaluating EDG-7500, a novel oral, selective, cardiac sarcomere modulator with a unique mechanism of action, in the ongoing phase II CIRRUS-HCM study. The latest data readout is from Part ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for EWTX is 70.

Earlier this month, John R. Moore, the GC of EWTX sold 70,922.00 shares for a total of $1,996,365.64. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing ...

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price target of $45.00. The company’s shares closed ...

Shares of Edgewise Therapeutics EWTX were up more than 18% on Monday after it announced positive results from the mid-stage CANYON study on its lead pipeline drug, sevasemten, in patients with a ...

A scientist in a lab coat using a microscope to study a cultured biopharmaceutical product. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds.